Trials / Completed
CompletedNCT02362958
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Sun Yat-sen University Cancer Center
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the Efficacy of Lapatinib in Combination With Chemotherapy in Patients With Trastuzumab-refractory Metastatic HER2-positive Breast Cancer.
Detailed description
Some studies has demonstrated that even in trastuzumab pretreated patients with HER-2 positive breast cancer, might benefit from the treatment of trastuzumab. However, there is small benefit for some patients having short disease-free survival after adjuvant trastuzumab or short progression-free survival after first-line trastuzumab-based therapy. In clinical practice, the investigators also found it is fact. And the investigators have a scientific rationale for clinical testing of lapatinib plus chemotherapy in patients with trastuzumab-refractory, metastatic HER2-positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib and capecitabine or vinorelbine | lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8) |
Timeline
- Start date
- 2015-01-09
- Primary completion
- 2020-05-31
- Completion
- 2020-05-31
- First posted
- 2015-02-13
- Last updated
- 2020-07-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02362958. Inclusion in this directory is not an endorsement.